Full Text View
Tabular View
No Study Results Posted
Related Studies
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
This study has been completed.
First Received: April 15, 2003   Last Updated: August 4, 2008   History of Changes
Sponsor: Alcon Research
Information provided by: Alcon Research
ClinicalTrials.gov Identifier: NCT00058994
  Purpose

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.


Condition Intervention Phase
Macular Degeneration
Maculopathy, Age-Related
Drug: anecortave acetate
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Study Start Date: March 2003
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00058994

Locations
United States, Texas
South America
Fort Worth, Texas, United States
Sponsors and Collaborators
Alcon Research
Investigators
Principal Investigator: Alcon Investigators Alcon Research
  More Information

No publications provided

Study ID Numbers: C-02-29
Study First Received: April 15, 2003
Last Updated: August 4, 2008
ClinicalTrials.gov Identifier: NCT00058994     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Alcon Research:
AMD
anecortave acetate
wet AMD
age-related macular degeneration
Macular Degeneration
Maculopathy, Age-Related
Age-Related Maculopathies
Age-Related Maculopathy
Maculopathies, Age-Related

Additional relevant MeSH terms:
Uveal Diseases
Pathologic Processes
Metaplasia
Eye Diseases
Choroid Diseases
Retinal Degeneration
Macular Degeneration
Neovascularization, Pathologic
Retinal Diseases
Choroidal Neovascularization

ClinicalTrials.gov processed this record on November 09, 2009